Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    155
    ...
ATC Name B/G Ingredients Dosage Form Price
B01AC04 AGGRIX 75 G Clopidogrel besylate - 75mg 75mg Tablet, film coated 1,204,083 L.L
J01FA10 AZICIN 250 BENTA G Azithromycin - 250mg 250mg Tablet, film coated 423,630 L.L
A10BD02 GLUCOVANCE B Metformin HCl - 500mg, Glibenclamide - 2.5mg Tablet, film coated 542,192 L.L
B01AC04 ANTIPLEX G Clopidogrel (Bisulfate) - 75mg 75mg Tablet, film coated 1,295,464 L.L
C10AA01 BELMALIP G Simvastatin - 20mg 20mg Tablet, film coated 716,268 L.L
J01FA10 AZIFAST 250 G Azithromycin - 250mg 250mg Tablet, film coated 423,630 L.L
L02BG06 EXEMESTANE GENEPHARM G Exemestane - 25mg 25mg Tablet, film coated 1,286,662 L.L
C10AA01 SIMVASTATIN NORMON G Simvastatin - 20mg 20mg Tablet, film coated 264,737 L.L
L02BG06 EXEMESTANE GP PHARM G Exemestane - 25mg 25mg Tablet, film coated 1,158,392 L.L
A10BD02 GLUCOVANCE B Metformin HCl - 500mg, Glibenclamide - 5mg Tablet, film coated 746,412 L.L
C10AA01 SIMVASTATIN-REMEDICA G Simvastatin - 20mg 20mg Tablet, film coated 542,912 L.L
A04AA01 ZOFRAN B Ondansetron (HCl dihydrate) - 8mg 8mg Tablet, film coated 6,061,174 L.L
A10BD02 DIAMET 500/5 G Metformin HCl XR - 500mg, Glibenclamide - 5mg Tablet, film coated 639,925 L.L
B01AC04 CLOPI TAD G Clopidogrel (Bisulfate) - 75mg 75mg Tablet, film coated 911,125 L.L
G04BD02 URISPAS B Flavoxate HCl - 200mg 200mg Tablet, film coated 1,094,272 L.L
L01EB02 MIRATA G Erlotinib (HCl) - 100mg 100mg Tablet, film coated 77,379,009 L.L
R06AX22 EBASTEL B Ebastine - 10mg 10mg Tablet, film coated 722,987 L.L
A10BD02 GLUCOVANCE B Metformin HCl - 1000mg, Glibenclamide - 5mg Tablet, film coated 967,891 L.L
B01AC04 CLOPIDOGREL ARROW G Clopidogrel besylate - 75mg 75mg Tablet, film coated 658,483 L.L
L01EB02 TARESSA 100 G Erlotinib (HCl) - 100mg 100mg Tablet, film coated 82,247,256 L.L
L02BX03 ABIRATERONE ACETATE SPC G Abiraterone acetate - 250mg 250mg Tablet, film coated 92,278,660 L.L
M01AE01 BRUFEN B Ibuprofen - 600mg 600mg Tablet, film coated 407,003 L.L
N06AB06 RESTRALINE G Sertraline HCl - 50mg 50mg Tablet, film coated 575,933 L.L
A10BD02 GLIBOMET B Metformin HCl - 400mg, Glibenclamide - 5mg Tablet, film coated 462,282 L.L
C10AA01 SIMVASTATIN NORMON G Simvastatin - 40mg 40mg Tablet, film coated 264,737 L.L
J01FA10 ZEVLEN G Azithromycin (dihydrate) - 250mg 250mg Tablet, film coated 409,552 L.L
R06AX26 EXOFEN G Fexofenadine HCl - 120mg 120mg Tablet, film coated 287,582 L.L
A04AA01 NOZENTRIX G Ondansetron - 8mg 8mg Tablet, film coated 1,075,074 L.L
B01AC04 CLOTRIX 75 G Clopidogrel (hydrogenosulfate) - 75mg 75mg Tablet, film coated 1,109,630 L.L
C09AA04 COVERSYL ARGININE B Perindopril arginine - 10mg 10mg Tablet, film coated 452,875 L.L
    ...
    155
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025